Photobiomodulation to Boost CAR-T Cell Therapy for B-Cell Cancers
Official title: Photobiomodulation-Enhanced CAR-T Cell Therapy
Funded at Case Western Reserve University · NIH-11437508 · Data updated 2026-11-12
A patient-facing overview of using light-based therapy to improve CAR-T cell treatment for B-cell cancers, aiming for better effectiveness and lower costs.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | August 1, 2026 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $393,812 |
| NIH project number | 1R21CA318125-01 |
| Project ID | NIH-11437508 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with B-cell malignancies who are candidates for CAR-T cell therapy.
✕Less likely to help
Patients who are not eligible for CAR-T or do not have B-cell malignancies may not benefit from this approach.
What this research studies
This project explores using safe, non-invasive light therapy (photobiomodulation) to make CAR-T cells grow stronger and persist longer after they are made for treating B-cell cancers. Researchers will test different light wavelengths and dosing plans in the lab to see how these cells' energy production and survival improve, without changing their genetic makeup. If successful, the approach could translate to faster manufacturing, better tumor-killing activity, and potentially lower treatment costs. The work includes lab studies of CAR-T cells and animal models to understand how light affects metabolism and effectiveness. It is designed to be GMP-compatible and move toward real-world clinical use.
Why it matters
Potential benefit: If successful, patients could receive more effective CAR-T therapy with longer-lasting responses and potentially lower treatment costs.
How similar studies have gone: Early lab data suggest that photobiomodulation can boost CAR-T cell functions, supporting potential benefit in humans.
Where this research is happening
-
Case Western Reserve University
Cleveland, United States Active
Researchers
- Principal investigator: Jenkins, Michael W. — Case Western Reserve University
- Study coordinator: Jenkins, Michael W.
Related research
Other NIH-funded projects on the same topics.
-
SynthNode: A new, easier way to make CAR T cells for better cancer treatment
A new implantable device called SynthNode could simplify and lower the cost of CAR T cell therapy, helping patients with lymphoma, myeloma, and potentially solid tumors or lupus.
-
Intraperitoneal CAR T cells for peritoneal mesothelioma
A new approach uses CAR T cells delivered directly into the abdominal cavity to target mesothelioma, aiming to help people whose disease is confined to the abdomen.
-
Targeting death receptors to boost MET-CAR T cells for glioblastoma
Aims to make MET-CAR T cells work better against glioblastoma by using radiation to trigger death receptors on tumor cells.
-
CTO1681: reducing dangerous immune reactions in patients getting CAR T-cell therapy
A new oral drug (CTO1681) aims to prevent and lessen cytokine release syndrome in patients with blood cancers treated with CAR T-cell therapy.
-
CD2-targeted CAR-T therapy for T-cell lymphoma in a multi-center program
A patient-focused overview of a research grant that aims to improve CAR-T cell therapy for T-cell lymphoma by exploring CD2 as a new target and enhancing allogeneic CAR-T safety features.
-
B7-H3 CAR-T therapy for pancreatic cancer in a phase I study
A new CAR-T treatment targeting B7-H3 is being tested in people with pancreatic cancer to see if it is safe and helps fight tumors.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.